Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HRH1 | P35367 | 1/20 | 0.39 |
| ▸ | HRH4 | Q9H3N8 | 1/20 | 0.39 |
| ▸ | BAZ2B | Q9UIF8 | 1/20 | 0.34 |
| ▸ | FDPS | P14324 | 1/20 | 0.32 |
| ▸ | CYP2A6 | P11509 | 1/20 | 0.31 |
| ▸ | TSHR | P16473 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL18870502 | 0.84 | HRH1 (0.37) | HRH1HRH4BAZ2BFDPS | |
| SCHEMBL20257974 | 0.81 | HRH1 (0.41) | HRH1HRH4BAZ2BFDPSCYP2A6 | |
| SCHEMBL18870444 | 0.78 | GPR84 (0.41) | HRH1HRH4 | |
| SCHEMBL3188691 | 0.78 | — | — | |
| SCHEMBL22508894 | 0.78 | — | — | |
| SCHEMBL18870395 | 0.76 | CHRNB2 (0.32) | HRH1HRH4BAZ2B | |
| SCHEMBL27922421 | 0.75 | — | — | |
| SCHEMBL27941032 | 0.72 | — | — | |
| SCHEMBL28955057 | 0.71 | — | — | |
| SCHEMBL18410438 | 0.71 | LMNA (0.32) | TSHR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-10028937-B2 | Anti-viral compounds | ABBVIE INC. (US) | 2018-07-24 | — | — | US | disclosed |
| US-20170157105-A1 | Anti-Viral Compounds | ABBVIE INC. (US) | 2017-06-08 | — | — | US | disclosed |
| EP-2900656-B1 | SPIRO RING COMPOUNDS AS HEPATITIS C VIRUS (HCV) INHIBITORS | SUNSHINE LAKE PHARMA CO LTD (CN) | 2017-05-17 | — | — | EP | disclosed |
| US-9580425-B2 | Pyrido[3,4-b] indoles and methods of use | MEDIVATION TECHNOLOGIES, INC. (US) | 2017-02-28 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10028937-B2 | Anti-viral compounds | HAVCR2, EIF2AK2, MAVS | HRH1 3557/4885HRH4 3857/4885BAZ2B 1677/4885 |
| US-20170157105-A1 | Anti-Viral Compounds | HAVCR2, EIF2AK2, MAVS | HRH1 3557/4885HRH4 3857/4885BAZ2B 1677/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.